Here are five points:
1. An increase in funding to advance orthobiologics will spur market growth.
2. Many vendors are investing in research for new product development.
3. Strategic marketing partnerships will also drive market growth.
4. Spinal fusion costliness will hinder orthobiologics’ sales.
5. Key market players include DePuy Synthes, Medtronic, Sanofi, Stryker and Zimmer Biomet.
More articles on devices:
Providence Medical Technology DTRAX system boasts positive results for cervical radiculopathy treatment: 5 takeaways
Medtronic, NuVasive lead US MIS interbody fusion market: 7 observations
Atlas Spinal Care to offer new cervical radiculopathy treatment: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
